Qiagen Sees Huge Revenue Potential in Applied Markets, But Maintains Focus on Molecular Dx | GenomeWeb

The applied testing market will represent a $5 billion opportunity by 2008, and Qiagen expects its preanalytical technologies to play a significant role in that segment, CEO Peer Schatz said during a presentation to analysts and investors in New York last week.

Even though this market currently represents around half of Qiagen's total sales, Schatz said the firm will remain primarily focused on growing its molecular diagnostics business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.